College of Pharmacy, Dongguk University, Seoul 100-715, Republic of Korea.
National Cancer Center, Goyang 10408, Republic of Korea.
Biochem Pharmacol. 2021 Jan;183:114339. doi: 10.1016/j.bcp.2020.114339. Epub 2020 Nov 13.
Lung cancer is one of the leading causes of death in cancer patients. Epithelial-mesenchymal transition (EMT) plays an important role in lung cancer progression. Therefore, for lung cancer treatment, it is crucial to find substances that inhibit EMT. Ethacrynic acid (ECA) is a diuretic that inhibits cellular ion flux and exerts anticancer effects. However, the effects of ECA on EMT in lung cancer remain unclear. We examined the effects of ECA on sphingosylphosphorylcholine (SPC) or TGF-β1-induced EMT process in A549 and H1299 cells via reverse transcription polymerase chain reaction and Western blotting. We found that ECA inhibited SPC-induced EMT and SPC-induced WNT signalling in EMT. We observed that SPC induces the expression of NDP [Norrie disease protein] and WNT-2, whereas ECA suppressed their expression. SPC-induced WNT activation, EMT, migration, and invasion were suppressed by NDP small-interfering RNA (siNDP), but NDP overexpression (pNDP) enhanced these events in A549 and H1299 cells. Accordingly, NDP expression may influence lung cancer prognosis. In summary, our results revealed that ECA inhibited SPC or TGF-β1-induced EMT in A549 and H1299 lung cancer cells by downregulating NDP expression and inhibiting WNT activation. Therefore, ECA might be a new drug candidate for lung cancer treatment.
肺癌是癌症患者死亡的主要原因之一。上皮-间充质转化(EMT)在肺癌进展中起着重要作用。因此,对于肺癌的治疗,找到抑制 EMT 的物质至关重要。依他尼酸(ECA)是一种利尿剂,可抑制细胞离子流并发挥抗癌作用。然而,ECA 对肺癌 EMT 的影响尚不清楚。我们通过逆转录聚合酶链反应和 Western blot 检测 ECA 对 SPC 或 TGF-β1 诱导的 A549 和 H1299 细胞 EMT 过程的影响。我们发现 ECA 抑制了 SPC 诱导的 EMT 和 EMT 中的 WNT 信号。我们观察到 SPC 诱导 NDP [诺里病蛋白]和 WNT-2 的表达,而 ECA 则抑制其表达。SPC 诱导的 WNT 激活、EMT、迁移和侵袭被 NDP 小干扰 RNA(siNDP)抑制,但在 A549 和 H1299 细胞中,NDP 过表达(pNDP)增强了这些事件。因此,NDP 的表达可能影响肺癌的预后。总之,我们的结果表明,ECA 通过下调 NDP 表达和抑制 WNT 激活,抑制 SPC 或 TGF-β1 诱导的 A549 和 H1299 肺癌细胞 EMT。因此,ECA 可能是治疗肺癌的一种新的候选药物。